Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 898123 | ISIN: US9418481035 | Ticker-Symbol: WAZ
Tradegate
12.11.24
17:19 Uhr
362,60 Euro
+5,10
+1,43 %
Branche
Sonstige Technologie
Aktienmarkt
S&P 500
1-Jahres-Chart
WATERS CORPORATION Chart 1 Jahr
5-Tage-Chart
WATERS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
360,90362,8021:06
360,90362,8021:06
PR Newswire
125 Leser
Artikel bewerten:
(0)

Waters Corporation: Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness

Finanznachrichten News

News Summary:

  • waters_connect Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data throughout the product development lifecycle, enabling real-time audit readiness and query response, while reducing time spent on audit preparation.

  • Cloud-based software proactively provides visibility into risks that could trigger adverse regulatory findings, delivering seamless remote data access, comprehensive analytics, historical trends, scalability, and cost efficiency.

  • Provides actionable insights from Waters Empower CDS software to help prevent system suitability failures, that can cost up to $600,000 per year.i

MILFORD, Mass., Nov. 7, 2024 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced waters_connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organize, analyze, and drive productivity from laboratory information. The software leverages data from Waters Empower Chromatography Data System (CDS) enabling laboratories to achieve confident audit-readiness, helping laboratory managers respond more quickly to audit inquiries with insights, and making informed decisions faster.

"Organizations need to ensure there are no missteps with data quality and integrity to avoid product release delays and failed quality regulatory audits that can cost tens of millions of dollars and delay lifesaving treatments," said Dave Leitham, Vice President, Connected Science at Waters Corporation. "waters_connect Data Intelligence software provides organizations with a new level of transparency into their data, making it easier to analyze and deliver valuable operational and scientific insights in real time, thus enhancing readiness for business-critical audits."

Designed to work with Empower CDS, waters_connect Data Intelligence software generates in-depth, configurable dashboards that deliver advanced analytical insights on laboratory data such as aborted injections and sample sets to help reduce the risks associated with adverse findings in regulatory audits. Where users of Empower CDS can take, on average, two days to respond to an auditor's question,ii they can instead avoid costly manual data consolidation and interpretation that could lead to data analysis errors.

waters_connect Data Intelligence software is designed to work seamlessly with Empower today and in the future, eliminating costly integrations to homegrown or external applications. It provides real-time remote data access, seamless tracking of long-term trends and patterns, and always reflects the latest data from any Empower-connected instrument. The software enables trending of method, column, and instrument suitability data, which helps preempt failures before they happen. The annual cost of system suitability failures in pharma laboratories is estimated to be $600,000 based on two failures per month.

"From the early demos and usage of the new software, we really like the flexibility that the waters_connect Data Intelligence tool offers for tracking system usage, column shelf-life, and user utilization," said Donny Preiss, Associate Director, IT Lab Applications at biopharmaceutical company, MannKind Corporation. "The new software will allow for streamlined processes in our laboratory, more meaningful data usage, and quicker business decisions."

waters_connect Data Intelligence software can be tailored to organizations with single or multiple Empower CDS instances and is available for demonstration and quoting now, and to order in December 2024.

Additional Resources

  • Learn more at waters_connect Data Intelligence
  • Link to the product brochure and infographic
  • Follow and connect with Waters via LinkedIn, Twitter, and Facebook

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, waters_connect, and Empower are trademarks of Waters Technologies Corporation.

Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
janice_foley@waters.com
+1.617.823.5555

____________________________

i Based on an average cost of $25,000 per failure, including a batch release delay of 48 hours for a typical small molecule drug, according to data acquired from a cohort of 19 customers during Waters User Executive studies. As an illustrative example of two system suitability failures per month, the average annual cost can be $600,000.


iiBased on Waters internal analysis and estimates.

Waters Corporation

Logo - https://mma.prnewswire.com/media/2071755/Waters_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/waters-new-software-delivers-lab-centric-business-intelligence-and-enables-confident-audit-readiness-302298147.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.